BioSpace News Archive

Single Pass, with the first and only biopsy closure cauterization device, is delighted to announce the successful completion of the first real- life cases utilizing the groundbreaking device.

Poolbeg Pharma announces that it has received notification that on 19 February 2024, Cathal Friel, Executive Chairman of the Company, purchased 830,000 ordinary shares at a price of 11.68 pence per share.

hyperCORE International is pleased to announce the appointment of two distinguished industry leaders to its executive team, effective immediately.

American Aires Inc. (CSE: WIFI) (OTC Pink: AAIRD) (“Aires” or the “Company”), a company focused on scientifically-proven EMF modulation technology, announces the closing of its non-brokered private placement offering (the “Offering”) of 26,666,663 units of the Company (the “Units”)

Amgen (NASDAQ:AMGN) will host a webcasted call at 1:00 p.m. PT on Thursday, February 22, 2024 to discuss Rare Disease, its newly added fourth pillar of growth, and provide insights on its rare disease strategy and opportunities, including marketed products and pipeline.

Certa Therapeutics announces that the U.S. Food and Drug Administration has granted Fast Track Designation for its investigational therapy FT011 for the treatment of systemic sclerosis, having previously granted Orphan Drug Designation.

AstraZeneca and Daiichi Sankyo’s Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been accepted in the US for the treatment of adult patients with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) who have received prior systemic therapy.

OpenFold announced the release of two new tools: 1) SoloSeq, which integrates a new protein Large Language Model with its OpenFold structure prediction software, and 2) OpenFold-Multimer software, which creates higher quality models of protein/protein complexes than OpenFold alone.

Positive high-level results from the LAURA Phase III trial showed AstraZeneca’s TAGRISSO® (osimertinib) demonstrated a statistically significant and highly clinically meaningful improvement in progression-free survival (PFS) for patients with unresectable, Stage III epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after chemoradiotherapy (CRT) compared to placebo after CRT.

Medigene AG will present at the 7th CAR-TCR Summit Europe taking place February 27-29, 2024, in London as well as at the East-West Biopharma Summit to be held March 4-6, 2024, in Singapore.